|
Press Releases |
|
 |
|
Wednesday, April 14, 2021 |
|
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting |
Eisai Co., Ltd. announced today that the company will conduct presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401). more info >> |
|
Monday, April 12, 2021 |
|
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021 |
Eisai Co., Ltd. announced that its animation "Leave No One Behind-Disease of Neglected People" which features activities for the elimination of lymphatic filariasis (LF) has received the Animation Award at the International Society for Neglected Tropical Diseases (ISNTD) Festival 2021. more info >> |
|
Wednesday, March 31, 2021 |
|
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries |
KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., and Eisai Co., Ltd. have entered into a license agreement for development and distribution of vibegron, a therapeutic agent for overactive bladder, in four ASEAN (Association of Southeast Asian Nations) member states; Thailand, the Philippines, Malaysia and Brunei. more info >> |
|
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan |
Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co., Inc., (known as MSD outside the United States and Canada) announced today that Eisai has submitted an application in Japan for the additional indication of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor, LENVIMA. more info >> |
|
Tuesday, March 30, 2021 |
|
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab |
Eisai Co., Ltd. announced today that the European Medicines Agency (EMA) has confirmed it has accepted for review applications for the use of its in-house discovered multiple receptor tyrosine kinase inhibitor, lenvatinib mesylate, in combination with anti-PD-1 therapy pembrolizumab. more info >> |
|
Friday, March 26, 2021 |
|
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021 |
Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel, the AMPA-type glutamate receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2021 by the PSJ. more info >> |
|
Tuesday, March 23, 2021 |
|
Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan |
Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma. more info >> |
|
Monday, March 22, 2021 |
|
Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan |
Eisai Co., Ltd. announced today that, as part of one strategic investment towards the realization of its medium-term business plan "EWAY2025", it has conducted the groundbreaking ceremony for the construction of a new injection/research building "Eisai Medicine Innovation Technology Solutions" ("EMITS") at the Kawashima Industrial Park located in Gifu Prefecture, Japan. more info >> |
|
Eisai Awarded The New Diversity Management Selection 100 |
Eisai Co., Ltd. announced today that it was selected as one of winners of the Ministry of Economy, Trade and Industry (METI) Minister's Award of the New Diversity Management Selection 100 by METI. This marks the first time to be awarded ever since Eisai was included in the New Diversity Management Selection 100 Program. more info >> |
|
Wednesday, March 17, 2021 |
|
DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders |
Deutsches Zentrum fur Neurodegenerative Erkrankungen and Eisai Co., Ltd. today announced that both parties have entered into a research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders including Alzheimer's disease (AD) which modulate immune competence in neurons and glia cells. more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
DataBurning and Vumonic Announce Strategic Partnership for India E-Receipt Data
Apr 30, 2025 13:23 HKT/SGT
|
|
|
Ministry of Hajj and Umrah Emphasizes: 'No Hajj Without a Permit'
Apr 30, 2025 09:30 HKT/SGT
|
|
|
Melbourne's Deputy Lord Mayor shares city's path forward at PropertyGuru Asia Property Awards (Australia) launch
Apr 29, 2025 23:58 HKT/SGT
|
|
|
Katalon Officially Launches TrueTest(TM) - The First AI-Native Testing System That Thinks Like a Tester and Learns from Users
Apr 29, 2025 22:00 HKT/SGT
|
|
|
Global Sports Brand U.S. Polo Assn. Delivers Record $2.5 Billion in Retail Sales for 2024, Targets $3 Billion and 1,500 U.S. Polo Assn. Stores
Apr 29, 2025 19:00 HKT/SGT
|
|
|
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of Large Car Ferry KEYAKI in Shimonoseki
Apr 29, 2025 17:24 JST
|
|
|
Open Dialogue 'Future of the World. New Platform for Global Growth' Launches at Russia National Centre
Apr 29, 2025 15:00 HKT/SGT
|
|
|
The Apipatana Foundation Donates S$50,000 to Support Lower-Income Students in Singapore
Apr 29, 2025 15:00 HKT/SGT
|
|
|
HKTDC's April lifestyle fairs open today
Apr 29, 2025 12:42 HKT/SGT
|
|
|
HydroFleet Propels Hydrogen Revolution Forward With HTWO Logistics Collaboration in Savannah, GA
Apr 29, 2025 09:10 HKT/SGT
|
|
|
Azurite Medical and Wellness Launches Revolutionary Luxury Surgical Retreat Concept in Global Medical Tourism Market
Apr 29, 2025 02:09 HKT/SGT
|
|
|
Hong Kong International Licensing Show and Asian Licensing Conference Open Today
Apr 28, 2025 22:46 HKT/SGT
|
|
|
Hung Fook Tong Partners with Nutribite to Launch AI-Powered Personalised Healthy Meal Service
Apr 28, 2025 15:51 HKT/SGT
|
|
|
Q2 Metals Extends Mineralized Zone Strike Length to 1.5 Kilometres and Concludes the 2025 Winter Program at the Cisco Lithium Project in Quebec, Canada
Apr 28, 2025 15:05 HKT/SGT
|
|
|
NEC DGDF Headquarters relocates to Zurich to accelerate growth and enhance management globally
Apr 28, 2025 16:03 JST
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|